{"preliminary_commentary":{"by_channel":{"x_thread":11,"podcast":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04266301\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"STIMULUS-MDS2","nct_id":"NCT04266301","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stimulus-mds2-nct04266301. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"STIMULUS-MDS2","arms":[{"description":"Participants received sabatolimab plus Azacitidine","label":"Sabatolimab (MBG453) + Azacitidine","type":"EXPERIMENTAL"},{"description":"Participants received placebo plus Azacitidine.","label":"Placebo + Azacitidine","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-10-02","type":"ACTUAL"},"conditions":["Myelodysplastic Syndromes","Leukemia, Myelomonocytic, Chronic"],"enrollment":{"count":530,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Sabatolimab","otherNames":["MBG453"],"type":"DRUG"},{"name":"Azacitidine","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-01-13","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-10-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS) (Primary Efficacy Results)","timeFrame":"up to approx. 39 months"},{"measure":"Overall Survival (OS) (Final Efficacy Results)","timeFrame":"up to approx. 52 months"}],"references":[{"citation":"Zeidan AM, Giagounidis A, Sekeres MA, Xiao Z, Sanz GF, Hoef MV, Ma F, Hertle S, Santini V. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future Oncol. 2023 Mar;19(9):631-642. doi: 10.2217/fon-2022-1237. Epub 2023 Apr 21.","pmid":"37083373","type":"DERIVED"}],"start_date":{"date":"2020-06-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)","url":"https://clinicaltrials.gov/study/NCT04266301"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stimulus-mds2-nct04266301"}